Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Vanda Pharmaceuticals Provides Update on Tradipitant Development Program

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant.

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 (COVID-19) pneumonia in the...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 9.26 (-0.86%)
Vanda: 2Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported second-quarter net income of $8.7 million.

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ) today announced financial and operational results for the second quarter ended .

VNDA : 9.26 (-0.86%)
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceut (VNDA)

SmarTrend identified a Downtrend for Vanda Pharmaceut (NASDAQ:VNDA) on April 2nd, 2020 at $10.30. In approximately 3 months, Vanda Pharmaceut has returned 15.49% as of today's recent price of $11.89.

VNDA : 9.26 (-0.86%)
Vanda Pharmaceut Falls 6.36% on Heavy Volume: Watch For Potential Rebound

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $10.76 to a high of $11.38. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceut Falls 2.16% on Heavy Volume: Watch For Potential Rebound

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $10.83 to a high of $11.21. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from , M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceut (VNDA)

SmarTrend identified a Downtrend for Vanda Pharmaceut (NASDAQ:VNDA) on April 2nd, 2020 at $10.30. In approximately 2 months, Vanda Pharmaceut has returned 13.65% as of today's recent price of $11.70.

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on , it has reached...

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 9.26 (-0.86%)
Vanda: 1Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported first-quarter net income of $486,000, after reporting a loss in the same period a year earlier.

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ) today announced financial and operational results for the first quarter ended .

VNDA : 9.26 (-0.86%)
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on , after the market closes.  

VNDA : 9.26 (-0.86%)
Vanda Pharmaceut Up 14.3% Since SmarTrend Uptrend Call (VNDA)

SmarTrend identified an Uptrend for Vanda Pharmaceut (NASDAQ:VNDA) on April 2nd, 2020 at $10.30. In approximately 3 weeks, Vanda Pharmaceut has returned 14.33% as of today's recent price of $11.77.

VNDA : 9.26 (-0.86%)
Company News for Apr 17, 2020

Companies in the news are: TSM, BK, LOVE, VNDA

BK : 33.17 (-2.36%)
TSM : 79.71 (-1.09%)
VNDA : 9.26 (-0.86%)
LOVE : 23.45 (-1.64%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar